Nuvectis Pharma, Inc.
Clinical trials sponsored by Nuvectis Pharma, Inc., explained in plain language.
Nuvectis Pharma, Inc.
NVCT
NASDAQ
A biopharmaceutical company developing precision medicines for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to outsmart resistant lung cancer Results expected Dec 2026 (estimated)
- New pill shows promise against tough cancers in early trial Results expected Mar 2027 (estimated)
- Can a new drug combo outsmart resistant lung cancer? Results expected Aug 2027 (estimated)